一名57岁男性在接受非霍奇金淋巴瘤的R-CHOP化疗期间出现了关节炎。
A 57-year-old man who developed arthritis during R-CHOP chemotherapy for non-Hodgkin lymphoma.
作者信息
Swaneveld F H, van Vugt R M, de Boer J P, Dijkmans B A C, Lems W F
机构信息
Department of Rheumatology, Slotervaart Hospital, Amsterdam, The Netherlands.
出版信息
Clin Rheumatol. 2008 Feb;27(2):249-51. doi: 10.1007/s10067-007-0704-0. Epub 2007 Jul 28.
Rituximab is a chimeric human-mouse anti-CD20 monoclonal antibody, which is used in the treatment of both B-cell lymphomas and rheumatic diseases. We describe a case of a previously healthy 57-year-old man developing arthritis while being treated with rituximab-CHOP chemotherapy (R-CHOP) for a non-Hodgkin lymphoma. The remittant arthritis developed at successively shorter time-intervals after R-CHOP administration and only improved after rituximab was removed from the chemotherapy schedule, suggesting a rituximab-related phenomenon, as extensive diagnostic testing ruled out any other diagnosis.
利妥昔单抗是一种嵌合型人鼠抗CD20单克隆抗体，用于治疗B细胞淋巴瘤和风湿性疾病。我们描述了一例先前健康的57岁男性，在接受利妥昔单抗-CHOP化疗（R-CHOP）治疗非霍奇金淋巴瘤时出现关节炎。这种缓解性关节炎在R-CHOP给药后间隔时间越来越短出现，仅在化疗方案中停用利妥昔单抗后才有所改善，提示这是一种与利妥昔单抗相关的现象，因为广泛的诊断性检查排除了任何其他诊断。
Zotero 插件